A federal advisory committee has voted to recommend adding six peptides to the list of approved ingredients for medical compounding, a decision that has exposed significant divisions between recently appointed advisers and the Food and Drug Administration’s career scientists.
The Pharmacy Compounding Advisory Committee concluded a two-day hearing Friday by voting to recommend that BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax be added to the approved list of ingredients that specialty pharmacies may use to create custom medications. The vote remains non-binding and requires final approval from the FDA.
The committee rejected a seventh peptide, emideltide, citing particularly weak scientific evidence supporting its use.
Peptides are chains of amino acids, smaller in structure than proteins. While some peptides, such as insulin and GLP-1 medications, have undergone rigorous testing and received FDA approval, others have gained widespread popularity through social media despite limited clinical data. Online influencers have promoted these compounds as aids for muscle building and metabolic improvement, among other purported benefits.
The vote has revealed a substantial rift within the federal health establishment. Six of the eight recently appointed committee members operate clinics that offer peptide treatments. Meanwhile, FDA staff scientists unanimously opposed adding every peptide to the approved list, expressing concerns about insufficient clinical trial data, inconsistent manufacturing standards, and potential risks of harmful immune responses.
Health and Human Services Secretary Robert F. Kennedy Jr., who has oversight authority for the FDA, has publicly expressed support for peptide therapies.
Committee members who voted in favor of the recommendations defended their position as a harm reduction measure. They argued that their decision would direct consumers away from an expanding black market where individuals purchase these compounds from overseas sellers as unregulated “research chemicals” without medical supervision or quality guarantees.
“As a physician, I have to make sure that I am keeping patients as safe as possible,” committee member Dr. Haleem Mohammed stated Thursday. “So, when I look at something like saying no to this and pushing it to the gray market, am I doing greater harm? That is what I lose sleep at night over.”
Public health advocates and agency scientists have raised strong objections to this reasoning, warning that approving these peptides could establish a troubling precedent. Dr. Adriane Fugh-Berman, a professor of pharmacology, challenged the harm reduction argument by questioning whether the government would endorse manufacturing heroin simply because it might be cleaner than street alternatives.
The rejected peptide, emideltide, was proposed as a subcutaneous injection for treating narcolepsy and opioid withdrawal. However, the supporting clinical studies utilized an intravenous administration route. The evidence consisted of a single patient case report for narcolepsy and two small, uncontrolled studies for opioid withdrawal. The FDA noted that emideltide remains poorly understood and that well-tested, approved treatments already exist for both conditions.
The final decision now rests with FDA leadership, which must weigh the advisory committee’s recommendations against the unanimous opposition of its own scientific staff. The outcome will likely influence how millions of Americans access these increasingly popular but scientifically unproven compounds.
This matter represents a broader debate about balancing patient access to emerging treatments against established standards for medical evidence and drug safety.
Related: Thune Prioritizes Funding Extension Over Trump’s SAVE America Act
